TITLE

Recombinant FSH Versus HP-HMG for Controled Ovarian Stimulation in Intracitoplasmic Sperm Injection Cycles

AUTHOR(S)
Petanovski, Zoranco; Dimitrov, Gligor; Aydin, Byrol; Hadzi-Lega, Makjuli; Sotirovska, Valentina; Suslevski, Damjan; Saltirovski, Stefan; Matevski, Vladimir; Stojkovska, Snezana; Lazarova, Ana; Petanovska, Emilija; Balkanov, Trajan
PUB. DATE
June 2011
SOURCE
Medical Archives / Medicinski Arhiv;2011, Vol. 65 Issue 3, p153
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The aim of this study was to make a conclusion about aplicability of two differnet gonadothropins in COS (rFSH versus HP-hMG). he primary conclusion for the success as a result of COS are the mean number of retrived oocytes, mature oocytes, fertilization rate, mean number of quality embrios, and criopreverzed embrios. he secondary conclusions were clinical pregnancy rate and delivery rates. Methods: The study was a retrospective case-control study. A total of 1238 fresh, non donor, IVF cycles with COS were analyzed, but to minimize the bias, only the first cycle for each patient below 40 years old, in that period was analyzed. his selection composed the group of respondents that was analyzed which in total amounted to 760 patients.( rFSH = 422, HP-hMG = 338). he patients underwent COS by long luteal protocol using two different inducers of COS (rFSH and HP-hMG). Results: he average starting dose of rFSH used was significantely lower (152.7±41.1IU), whereas with HMG it was (228.8±68.7 IU, p=000000). he average number of IU gonadothropin used in therapy, statistically highly is significantly lower when r-FSH is used as an inducer. (1639.2 ± 476.9 IU, rFSH vs 2356.4 ± 955.1IU, HP-hMG, p <0.001). We received significantly higher average number of oocytes and mature oocytes in the group of r--FSH (oocytes; rFSH v HP-hMG--11.8 ± 7.1 v 10.7 ± 6.5, p = 0.028 ; mature oocytes: rFSH v HP-hMG 9.9 ± 6.2 v8.7 ± 5.5 p = 0.009). However, we did not find a significant difference in the use of the COS inductors regarding the clinical pregnancy rate (rFSH v HP-hMG 49.5% vs 48.9% p=0.92) and delivery rate (rFSH vs HP-hMG 42.9% vs 43.4% p=0.96). Conclusions: Our study showed that rFSH is more powerful and more applicable in individualized dosing then HP-hMG and brings better results from COS (more oocytes, more matured oocytes). Key words: Controled ovarian stimulation (KOS), rekominant folikulostimulative hormon (rFSH), high purity human menopausal gonadothropin (HP-hMG), intracitoplasmic sperm injection (ICSI), retrived oocytes.
ACCESSION #
66347069

 

Related Articles

  • Highly Purified hMG Produces Similar Outcome to Recombinant FSH.  // Fertility Weekly;1/5/2009, p3 

    The article focuses on a research conducted in Spain, according to which, the use of highly purified hMG (hp-hMG) produces similar implantation, clinical pregnancy and pregnancy loss rates as does the use of recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in luteinizing...

  • Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Scott M. Nelson; Robin W. Yates; Helen Lyall; Maybeth Jamieson; Isabel Traynor; Marco Gaudoin; Paul Mitchell; Pat Ambrose; Richard Fleming // Human Reproduction;Apr2009, Vol. 24 Issue 4, p867 

    : BACKGROUND Individualization of controlled ovarian stimulation (COS) for assisted conception is complicated by variable ovarian response to follicle stimulating hormone. We hypothesized that anti-Müllerian hormone (AMH), a predictor of oocyte yield, may facilitate treatment strategies for...

  • Random anti-Müllerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels. Celik, Handan; Bıldırcın, Devran; Güven, Davut; Cetinkaya, Mehmet; Alper, Tayfun; Batuoğlu, A. // Journal of Assisted Reproduction & Genetics;Aug2012, Vol. 29 Issue 8, p797 

    Objective: To evaluate the predictive value of random serum anti-Müllerian hormone (AMH) in the assessment of ovarian response in patients with diminished ovarian reserve (DOR; diagnosed after the observation of elevated baseline levels of early follicular follicle-stimulating hormone [FSH])...

  • Studies on the effects of initial injection doses of follicle stimulating hormone on the pregnancy and the ovarian hyperstimulation syndrome incidence in polycystic ovarian syndrome patients. Nakamura, Yasuhiko; Takasaki, Akihisa; Sugino, Norihiro; Tamura, Hiroshi; Takiguchi, Shuji; Takayama, Hisako; Harada, Ayako; Kato, Hiroshi // Reproductive Medicine & Biology;Jun2003, Vol. 2 Issue 2, p63 

    Background: Patients with polycystic ovarian syndrome (PCOS) are often resistant to clomiphene citrate, which causes the need for subsequent gonadotropin treatment. However, careful administration is required because of the potential side-effects, that is, ovarian hyperstimulation syndrome...

  • Clomiphene Citrate Challenge Testing and Pregnancy Response. Hendriks, D. J. // Fertility Weekly;2/5/2007, p8 

    The article discusses the study which aims to determine the predictive accuracy and clinical value of a single or repeated clomiphene citrate challenge test (CCCT) in predicting poor response in in vitro fertilization compared with other advocated basal ovarian reserve markers. In conclusion,...

  • Factors influencing response to ovarian stimulation. Keck, Christoph; Bassett, Robert; Ludwig, Michael // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Nov2005, Vol. 11 Issue 5, p562 

    Ovarian stimulation is an integral part of assisted reproduction treatments. Ovarian response to gonadotrophin treatment, besides other factors, determines the outcome of treatment, as the number and quality of oocytes retrieved are related to the chance of achieving a pregnancy. A number of...

  • Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes. P-H. Chen; Y-H. Lin; J-L. Hwang; L-W. Huang; S-C. Mu; K-M. Seow; J. Chung; B-C. Hsieh; S-C. Huang; C-Y. Chen // Human Reproduction;Aug2003, Vol. 18 Issue 8, p1632 

    BACKGROUND: The purpose of this study was to determine if there is any additional benefit from FSH priming in addition to hCG priming on in-vitro maturation (IVM) programmes. METHODS: Sixty women with polycystic ovary syndrome (PCOS) who underwent 68 IVM cycles were randomized by...

  • IVF treatment should not be postponed for patients with high basal FSH concentrations. Maman, Ettie; Baum, Micha; Machtinger, Ronit; Seidman, Daniel S.; Dor, Jehushua; Hourvitz, Ariel // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Nov2010, Vol. 21 Issue 5, p631 

    This study determined the influence of inter-cycle variation of basal FSH concentrations on IVF treatment results, in patients with a history of high basal FSH. Patients underwent at least two IVF cycles, one with basal serum FSH ≥ 10 IU/l and the other at least 3 IU/l tower (interval...

  • Repeated testing of basal FSH levels has no predictive value for IVF outcome in women with elevated basal FSH. H. Abdalla // Human Reproduction;Jan2006, Vol. 21 Issue 1, p171 

    BACKGROUND: It is a common practice to repeatedly test the level of basal FSH early in the cycle and to start IVF treatment only when the FSH level is below a certain threshold value. This is based on the idea that these women will respond better to ovarian stimulation when the basal FSH level...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics